Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer June 23, 2020June 23, 2020 by / Share This.....LinkedinTwitterFacebookGoogleEmailAgreement centers on identifying HER2 gene mutations using Oncomine Dx Target Test Related News: Roche’s VENTANA PD-L1 (SP263) Assay receives FDA…FDA Approves NGS-Based Companion Diagnostic for EGFR…Roche receives FDA approval for first companion…Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark…U.S. FDA approves Foundation Medicine’s…Thermo Fisher Scientific & Pfizer Partner to…
